Summit Therapeutics plc Summit Therapeutics Plc : Grant Of Share Options

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ("Summit" or the "Company") 
 
   GRANT OF SHARE OPTIONS 
 
   Oxford, UK, 28 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: 
SMMT), the drug discovery and development company advancing therapies 
for Duchenne muscular dystrophy and C. difficile infection, announces 
that on 27 June 2017 it granted share options over 34,711 new ordinary 
shares of 1p nominal value ("Shares") at an exercise price of 180 pence 
per Share to employees of the Company.  These options will vest in nine 
equal tranches on a quarterly basis from 27 June 2018 and will vest in 
full on 27 June 2020. 
 
   The above exercise price is the mid-market closing price of Summit's 
Shares on 26 June 2017. These option awards have been made under the 
Company's 2016 Long Term Incentive Plan. 
 
   This announcement contains inside information for the purposes of 
Article 7 of EU Regulation 596/2014. 
 
   - END - 
 
   For more information, please contact: 
 
 
 
 
Summit Therapeutics 
 Richard Pye (UK office)         Tel: [phone] 
 Erik Ostrowski (US office)      [phone] 
Cairn Financial Advisers LLP 
 (Nominated Adviser)             Tel: [phone] 
 Liam Murray / Tony Rawlinson 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

June 28, 2017 02:00 ET (06:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.